Cell line, strain and vectors engineering

MAMMALIAN PLATFORM

This strand of the research aims to accelerate the production of biologics—such as recombinant proteins, monoclonal antibodies (mAbs), and virus-like particles (VLPs)—using CHO and HEK293 cells.

By improving transient gene expression and pool-based systems, the team seeks faster, cost-effective alternatives to traditional clonal methods. Genomic and metabolic analyses, including CRISPR/Cas modifications, will help optimize cell performance.

Various transfection techniques and custom-designed promoters will also be explored to enhance protein yield and stability.

BACTERIAL PLATFORMS

This strand focuses on optimizing large-scale production of plasmid DNA and proteins using E. coli and B. subtilis, two well-established microbial platforms.

By refining strain selection, DNA design, and fermentation methods, the team aims to boost yields and efficiency. Advanced genetic engineering, including CRISPR-Cas9 and autolytic systems, will be used to streamline purification and reduce reliance on antibiotics.

Quality control and collaborations with industry partners will support the development of robust, scalable manufacturing solutions.